Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Just got an email alert from eTrade that AVXL has been initiated by Noble Financial as a buy at 16.0.
I see where Sheikh just posted again about CYDY.
In summary, we are excited about 2017 and have the following expectations:
• Completing enrollment in our Phase 3 PRO 140 combination trial and reporting initial efficacy results during the first half of 2017;
• Advancing recruitment in our Phase 3 monotherapy trial;
• Request a meeting with the FDA in the early part of the second quarter to discuss BLA submission;
• Presenting Phase 2b monotherapy results at CROI on February 15 and participating in a themed discussion session in elite company on February 16;
• Receiving notice from the FDA on Orphan Drug designation for PRO 140 in treatment-experienced HIV patients;
• Injecting the first patient in the Phase 2 GvHD trial;
• Submitting animal data in support of Orphan Drug Designation for GvHD;
• Announcing the publication of new animal data that further validates the effectiveness of PRO 140 in autoimmune disease and cancer; and
• Submitting all three sections of BLA to the FDA and request approval of PRO 140.
Letter to shareholders just posted...
Just out...VANCOUVER, Washington, Jan. 03, 2017 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency virus (HIV) infection, announces that management will hold an investment community conference call on Thursday, January 5, 2017, at 1:00 p.m. PT / 4:00 p.m. ET to provide an update on clinical trial and regulatory developments.
Management also announces that it will post a “Letter to Shareholders and Friends” from President and CEO Nader Pourhassan Ph.D. reviewing the Company’s progress and highlighting 2017 milestones to its corporate website at www.cytodyn.com on Thursday, January 5, 2017.
Misiu - I've been around here for a while, but there's still one thing that I'm missing, and I hope that you can help explain it given your medical background. As I understand it, the adjunct trial requires the patient to stay on their HAART meds while taking Pro140. So, what is the benefit for these patients to enroll in the adjunct trail and take Pro140 if they're still going to suffer the side effects from their HAART medication? Just curious as to whether this may be one of the reasons why it's been difficult for their CRO to find patients who are willing to enroll in the adjunct trial if there's no real benefit to going to the trial site every week and getting an injection. I understand their viral load may be less, but is that enough incentive?
Here's the website: http://www.doctoroz.com/contact
Yes, and if everyone emailed the Dr. Oz show asking when they're going to have Charlie give an update, would probably give us a significant bump.
The good news about this is the price is above Friday's close, and the warrants are at $1.00 - may help pull up the current pps.
Very well stated, Saltz! Couldn't have said it better myself!
Thank you, Saltz. With respect to the
I "had" many shares in another biotech stock that was in their phase 3 trials, and due to the many complaints about transparency, the CEO gave in to the stockholders' demands and started giving monthly enrollments updates. The pps was immediately pummeled by the shorts, and every month by short attacks following each monthly enrollment update. For this reason, the company then had to do a 1/12 reverse split to stay on the NYSE, and now they're struggling to raise cash to complete their P3 due to the very low pps - and all of this while experiencing positive results throughout their P3. When the shorts know that a trial has a way to go to completion, and they can estimate the completion date, they'll pummel it due to the low risk.
Options for 100k shares exercisable @ $.68/share for 10 years.
When someone says they need to have something done by tomorrow, they don't mean midnight today, or they would have said "today". If Dr. P meant that we would have the primary endpoints completed "before" Q1, he would have said "by the end of this year". When someone, especially in business, says they plan to complete something by "Q1", they're saying by March 31st. This is very common language.
Think of it this way, "by today" means "before tomorrow". By "Q1" means "before Q2" (Apr 1- June 30).
Do you now own 330k or 430k shares??
I suspect that many shareholders, including myself, believe that due to the slow enrollment, it may be Q1/2017 before we get any significant updates. Therefore some people may be "temporarily" moving some of their funds from here to other short-term investment opportunities with near-term catalysts. This would also explain the significant drop in pps following the CC. I also believe that the pps drop is only temporary and will move back up as we get close to the end of the year, when people repurchase their shares. There's too much risk to be out of this stock when we begin the new year.
It's much easier to borrow shares to short on the Nasdaq/NYSE than on OTC penny stocks. AVXL's pps has been brutalized since it moved off the OTC, and it's been a favorite target of shorts and orchestrated attacks from The Street, Motely Fool, etc.. My personal preference is to stay here below the radar until we have a major catalyst that can help protect us against the shorts and their attacks. If you think the little bit of shorting that's going on here is bad, you haven't seen anything yet...
5TOP - I don't think they're just now figuring out how it works - they've been saying for a long time that they're hoping to avoid the r/s by uplisting organically, which is obviously not happening as soon as they would like. Didn't one of their directors recently purchase a million shares? Probably not anxious to see their number of shares dramatically reduced due to a r/s.
I think you're confusing this with AVXL...
I never left. Just don't post very often, however I will add that I've been taking advantage of the very low share prices lately and have more than doubled my holdings in the last month. I see this as a very rare opportunity. IMHO, where else can you double your $'s in 6-12 months.
Given FDA has now reduced the number of patients by 90% (original 300 down to 30), CLEARLY FDA LIKES WHAT THEY'RE SEEING! They're basically paving the way to expedite PRO-140!
Charlie Sheen is on mono therapy - correct?
eTrade just issued the following BUY recommendation:
Just curious if anyone else has seen this article on why so many AD trials fail - may be due to a 2nd disease.
http://www.upi.com/Health_News/2016/10/03/Alzheimers-drug-trial-failures-may-be-due-to-second-disease/6531475497233/
I'm still waiting for Charlie to reappear on Dr. Oz as a follow up to his previous appearance. I believe the stock jumped 30-40% ?? the last time that he was on his show. He's given some good interviews but it would sure help if he was seen again on a show like Dr Oz's with a large American audience, and of course, mentions PRO140 and how well he's doing now that he's in the trial. I'm confident that he will appear again fairly soon.
Not sure if MBVX is a fair comparison - their volume is so low that it would be hard for shorts to drive the price down w/out NSS.
If they declare the S3 effective so they can fund the Rett's trial, why would you assume they're not still working on a partnership deal for the AD p2/p3 trial?
I agree, Tob. As the volatility and volume continues to decrease, the day traders will seek opportunities somewhere else, and the price will drift back up as the longs re-enter. It happens EVERY time.